Photo taken from Biagio Ricciuti/X
Apr 8, 2024, 23:10
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types is out in Cancer Discovery AACR Journals. In this study led by our stellar scientists Federica Pecci and Shesiru Nakazawa we identified that activating MET TKD mutations occur in multiple malignancies and can confer clinical sensitivity to currently available MET inhibitors. This study highlights the importance of performing comprehensive genomic tumor profiling to detect rare but targetable drivers.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 22, 2024, 08:13
Nov 21, 2024, 21:47
Nov 21, 2024, 21:40
Nov 21, 2024, 21:36
Nov 21, 2024, 21:27
Nov 21, 2024, 21:23
Nov 21, 2024, 21:17
Nov 21, 2024, 21:07